NOEL ILOGU: Open Payments
NPI 1518063551 · SOMERSET, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$834 in 45 payments from 18 companies in 2025. Trend: 2023 $353 · 2024 $840 · 2025 $834
Food & beverage: $834
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $188 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Novo Nordisk Inc | 5 | $74 |
| Braeburn Inc. | 4 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $55 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| Amgen Inc. | 3 | $49 |
| PFIZER INC. | 3 | $46 |
| Currax Pharmaceuticals LLC | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
Products named: CAPLYTA, REXULTI, BRIXADI, Wegovy, Kerendia, SPRAVATO, REPATHA, PREVNAR 20.
Industry payments across NJ — which companies pay providers there.
